Emcure Pharmaceuticals

    EMCURE
    Pharma
    ₹2,334.80
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹44,294 Cr

    P/E
    40.51
    Day range
    ₹2,326.00 – ₹2,402.00
    52-week range
    ₹1,312.30 – ₹2,429.90
    Volume
    2.56 L
    Open
    ₹2,354.90
    Prev close
    ₹2,339.40

    Latest results · Q2 FY27(consolidated)Revenue ₹2,820 Cr+24.3%Profit ₹325 Cr+29.3%Margin 11.5%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 70 / 100

    Factor percentiles

    Value35
    Quality70
    Momentum89
    Low volatility84

    Derived metrics

    Earn. yield
    2.5%
    Graham no.
    ₹606.30
    vs Graham
    -74.0%
    ROE ÷ P/B
    2.4%
    12-1 mom.
    +27.6%
    Return / vol
    1.93
    Magic Formula
    #244
    Piotroski
    6/6
    FCF yield
    0.9%
    PEG
    1.38

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Emcure PharmaceuticalsEMCURE₹44,294 Cr40.518.3820.0%24.0%21.0%0.34+24.2%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 9h ago

    Headlines about Emcure Pharmaceuticals from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    39.8
    Price / Book
    8.28
    ROE (FY26)
    20.0%
    ROCE (latest year)
    24%
    Dividend yield
    0.15%

    Moving averages (NSE)

    20-day
    ₹2,059.57
    Price above
    50-day
    ₹1,975.94
    Price above
    200-day
    ₹1,764.2
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +15.4%
    Profit 3Y CAGR
    +18.7%
    Revenue YoY (Sep 2026)
    +24.2%
    Profit YoY (Sep 2026)
    +29.5%
    Operating margin
    21.0%
    Net margin
    11.5%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr1K Cr2K Cr3K Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%15%30%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • DII
    • FII

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-2K Cr-1K Cr0 Cr1K Cr2K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY20FY21FY22FY23FY24FY25FY260%10%20%30%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr2K Cr4K Cr6K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 20260x1x2x

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales1,6681,7711,8152,0021,9632,1162,1012,2702,3632,4702,5802,820
    Expenses1,3741,4601,4791,6211,6081,7141,6841,7941,8711,9902,0482,233
    Operating Profit294311336381355402417475493480532588
    OPM %18%18%19%19%18%19%20%21%21%19%21%21%
    Other Income221223364-603-361423
    Interest616559463239273338463236
    Depreciation84919497979799105105106110110
    Profit before tax171167207273230261291341314341394446
    Tax %30%27%26%26%32%24%26%26%26%29%26%27%
    Net Profit120121153202156197215251231244292325
    EPS in Rs₹6.26₹6.36₹7.95₹10.29₹8.11₹9.97₹10.92₹12.84₹12.16₹12.84₹15.50₹17.16

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days102

    -5 days since Mar 2021

    Inventory Days239

    -54 days since Mar 2021

    Days Payable180

    -8 days since Mar 2021

    Cash Conversion Cycle161

    -51 days since Mar 2021

    Working Capital Days62

    +78 days since Mar 2021

    Strengths, risks & growth

    Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally [1]

    Strengths

    None flagged by the checklist.

    Risks

    • Stock is trading at 8.29 times its book value

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +13%
    3 Years
    +15%
    TTM
    +21%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +18%
    3 Years
    +21%
    TTM
    +39%

    Stock Price CAGR

    10 Years
    —
    5 Years
    —
    3 Years
    —
    1 Year
    +70%

    Return on Equity

    10 Years
    —
    5 Years
    +21%
    3 Years
    +19%
    Last Year
    +20%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter77.87%77.87%77.83%77.82%-0.01 pp
    FII3.59%3.35%4.87%4.94%+0.07 pp
    DII6.10%6.10%8.46%8.49%+0.03 pp
    Public12.43%12.69%8.84%8.75%-0.09 pp

    Filed with NSE for Sept 2026: promoters 77.82%, public 22.18%

    Analysts & fund holdings

    88%
    88% recommend buy
    8 analysts cover the stock
    Valuation vs Pharmaceuticals
    P/E40.5 vs 45.2
    Sector P/B6.05

    Who holds the shares, quarter by quarter

    Mutual funds 7.05% (+0.18 pp)
    Jun 25
    Sept 25
    Dec 25
    Mar 26
    Jun 26
    Sept 26
    • Promoters77.8%
    • Foreign institutions4.9%
    • Mutual funds7.0%
    • Insurance1.2%
    • Other domestic institutions0.3%
    • Retail2.9%
    • Others5.8%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    Kotak Mid Cap Fund1.82%1.25%+0.23 pp
    Aditya Birla SL ELSS Tax Saver Fund0.57%1.89%+0.09 pp
    Nippon India Multi Cap Fund0.55%0.46%-0.14 pp
    SBI Flexicap Fund0.49%0.98%+0.01 pp
    Axis Small Cap Fund0.43%0.65%+0.12 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    33.0%
    Downside volatility
    28.6%
    Worst 5% of days
    3.1%
    Average of that tail
    3.8%
    Max drawdown (1Y)
    12.7%
    Below its peak
    1.1%

    Against the market

    Beta vs Nifty 50
    0.54
    Correlation
    0.22
    Relative strength (3M)
    +20.7%
    ATR (14)
    3.3%

    Return

    Return 1M
    +28.2%
    Return 3M
    +24.6%
    Return 6M
    +38.5%
    Return 1Y
    +63.7%
    vs 200-day average
    +32.3%

    Momentum

    RSI (14) · overbought
    77.8
    MACD histogram
    33.45
    Stochastic %K
    87.9
    ADX (14)
    45.7
    +DI / −DI
    34.8 / 6.0
    Money flow index
    87.5

    Participation

    Delivery (20d avg)
    53.4%
    vs its 60-day baseline
    -0.4 pts
    Volume vs 20-day
    -0.1σ
    Close vs day's VWAP
    -0.8%
    52-week position
    98 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    6 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — passed
    • Current ratio improving — passed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    ₹396 Cr
    FCF yield
    0.9%
    Cash conversion
    1.00
    Accruals ratio
    -0.000
    Net debt
    ₹1,620 Cr
    Net debt / equity
    0.30
    EV / sales
    4.49
    PEG
    1.38
    Capex intensity
    6.0%
    Revenue CAGR
    21.1%
    Profit CAGR
    39.5%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Corporate actions

    • dividend
      ₹3.60

      Dividend - Rs 3.60 Per Share

      4 Sept 2026
      ex-date
    • dividend
      ₹3.00

      Dividend - Rs 3 Per Share

      14 Aug 2025
      ex-date

    Company announcements

    Company Update
    Intimation Of Cancellation Of Schedule Of Analyst/ Investor Meeting(S) Scheduled On November 16, 2026

    Intimation of Cancellation of schedule of Analyst / Investor Meeting(s) scheduled on November 16, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Transcript of Earnings Call - Q2 FY27 held on Tuesday, November 03, 2026 at 4:00 p.m. (IST)

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of schedule of Analyst/Investor Meeting dated Monday, November 16, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Intimation of schedule of Analyst/Investor Meeting on Monday, November 16, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Publication of Unaudited Financial Results of the Company for the quarter and half-year ended September 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    Audio recording of Earnings Call - Q2 FY27

    Company Update
    Announcement under Regulation 30 (LODR)-Investor Presentation

    Presentation on Unaudited Financial Results for the quarter ended September 30, 2026

    Result
    Approval Of Unaudited Financial Results

    Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026

    Board Meeting
    Board Meeting Outcome for Outcome Of Board Meeting Held On November 03, 2026

    For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation for Earnings Call - Q2 FY27

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Approval Of Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half-Year Ended September 30, 2026

    Emcure Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Unaudited Financial ....

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Confirmation under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026

    Company Update
    Announcement under Regulation 30 (LODR)-Scheme of Arrangement

    Proposed Scheme of Amalgamation of Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, wholly owned subsidiaries of the Company with Emcure Pharmaceuticals Limited - Holding ....

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order

    Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulatory Order(s)

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of Closure of Trading Window

    Filed with BSE (scrip 544210); the last 45 days. Documents open at bseindia.com.

    Documents

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Emcure Pharmaceuticals: common questions

    Answered from the figures on this page.

    Emcure Pharmaceuticals last traded at ₹2,334.80 (NSE, as of 18 Nov 2026). The last session moved it down 0.20%.

    Emcure Pharmaceuticals is valued at about ₹44,294 crore (NSE, as of 18 Nov 2026).

    Emcure Pharmaceuticals trades at a price-to-earnings ratio of 40.51 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Emcure Pharmaceuticals has traded between ₹1,312.30 and ₹2,429.90 over the past 52 weeks, to 18 Nov 2026. It is currently 91% of the way up that range.

    Emcure Pharmaceuticals (EMCURE) is classified under Pharma on this site's screener.